Clinical trials have traditionally depended on scheduled site visits, laboratory tests, clinician assessments, and patient-reported outcomes to determine whether a therapy is safe and effective. While these methods remain fundamental to clinical development, they provide only periodic snapshots of a patient’s health.
Digital biomarkers could significantly change this model.
Data generated through wearable devices, connected sensors, smartphones, and other digital health technologies can provide continuous and objective insights into a patient’s physiological or behavioral condition. Measurements related to movement, sleep, heart activity, respiratory patterns, cognition, and other functions can potentially be captured outside traditional clinical settings.
The result could be a transition from episodic clinical measurement toward continuous, real-world monitoring.
For pharmaceutical and biotechnology companies, however, the opportunity extends beyond collecting more data. Digital biomarkers could influence clinical trial design, patient recruitment, decentralized research, endpoint development, regulatory strategy, and evidence generation.
The critical question is no longer whether digital technologies will influence clinical trials. It is how effectively life sciences companies can convert digital measurements into clinically meaningful, validated, and regulatory-ready evidence.
From Clinical Snapshots to Continuous Patient Insights
One of the limitations of conventional clinical trials is that researchers typically observe patients at predefined intervals.
A participant may visit a clinical site every few weeks for assessments. What happens between those visits can be difficult to measure accurately.
Digital biomarkers offer a different approach.
Wearable sensors and connected technologies can potentially collect health-related information continuously while patients perform normal daily activities. Instead of relying exclusively on isolated measurements, researchers may gain a more comprehensive picture of disease progression and treatment response.
Depending on the disease and technology, digital measurements could capture factors such as:
- Physical activity and mobility
- Sleep patterns
- Heart rate and cardiovascular parameters
- Respiratory function
- Tremor and motor function
- Cognitive or behavioral changes
- Treatment adherence
This richer data environment could help researchers identify subtle changes that conventional assessments may overlook.
For diseases characterized by fluctuating symptoms, continuous monitoring may be particularly valuable.
Could Digital Biomarkers Transform Clinical Trial Endpoints?
One of the most important potential applications is the development of new clinical endpoints.
Traditional endpoints may not always capture subtle or early changes in disease progression. Digital technologies can potentially provide more sensitive measurements by collecting data frequently and in real-world environments.
Consider a neurological clinical trial.
Rather than evaluating mobility only during scheduled clinic assessments, wearable sensors could measure walking patterns, movement speed, balance, and activity continuously.
This could provide researchers with a more detailed understanding of whether a treatment is influencing patients’ everyday functional abilities.
However, generating large amounts of data does not automatically make a digital measurement clinically useful.
Digital biomarkers must demonstrate analytical reliability, clinical relevance, reproducibility, and suitability for the intended context of use.
This means validation will remain one of the most important challenges for companies developing digital endpoints.
Decentralized Trials Could Accelerate Adoption
Digital biomarkers also align closely with the growth of decentralized and hybrid clinical trials.
Traditional trials often require participants to travel repeatedly to research centers, creating logistical challenges that can affect recruitment and retention.
Remote monitoring technologies can potentially move parts of clinical research closer to patients.
Wearables, connected devices, telemedicine platforms, and remote assessments may allow certain data to be collected from participants in their everyday environments.
This could create several advantages.
Trials may become more accessible to geographically dispersed populations. Patient participation burdens could decrease. Researchers may also obtain data that better reflects real-world patient experiences.
For pharmaceutical companies, decentralized data collection could potentially improve recruitment and retention while creating more patient-centric clinical development models.
However, technology usability must remain a priority. A sophisticated digital tool provides limited value if patients find it difficult or burdensome to use consistently.
AI Could Unlock the Value of Continuous Data
Digital biomarkers generate enormous quantities of information.
The real opportunity emerges when artificial intelligence and advanced analytics transform these datasets into meaningful clinical insights.
Machine learning algorithms can potentially identify patterns within complex physiological and behavioral datasets that would be difficult to detect through conventional analysis.
AI-powered systems could help researchers:
- Identify early signs of disease progression
- Detect treatment-response patterns
- Segment patient populations
- Predict potential clinical outcomes
- Identify unusual safety signals
- Discover new digital endpoints
This creates an important convergence between digital health, artificial intelligence, and pharmaceutical R&D.
In the future, clinical trials may increasingly combine traditional clinical measurements with continuous digital data and AI-driven analysis.
The organizations that develop strong capabilities across these areas may gain advantages in trial design and evidence generation.
Regulatory Validation Will Determine Adoption
Despite their potential, digital biomarkers face an important challenge: regulatory acceptance.
Regulators require confidence that measurements used in clinical development are accurate, reliable, meaningful, and appropriate for their intended purpose.
Companies therefore need robust validation strategies.
This includes evaluating the technology used to collect data, the algorithms used to process it, the clinical relevance of the resulting measurement, and the consistency of performance across diverse patient populations.
Regulatory strategy should ideally begin early rather than after a digital endpoint has already been integrated deeply into development.
Early engagement can help companies understand evidence expectations and reduce the risk of investing heavily in measurements that may later face regulatory challenges.
As digital biomarkers mature, regulatory intelligence will become increasingly important for navigating evolving expectations across different markets.
Data Quality, Privacy and Interoperability Remain Challenges
The expansion of digital measurement introduces new operational complexities.
Clinical trials may use multiple wearable devices, software platforms, analytics systems, and data environments.
Ensuring that information can be collected consistently and integrated effectively is essential.
Companies must address issues including:
- Data standardization
- Device reliability
- Cybersecurity
- Patient privacy
- Algorithm transparency
- Technology interoperability
- Missing or inconsistent data
- Digital accessibility
Patient diversity is another important consideration.
Digital technologies must perform reliably across different ages, demographics, geographies, lifestyles, and levels of technological familiarity.
Otherwise, digital clinical research could unintentionally introduce new forms of bias.
A New Competitive Advantage for Biopharma?
Digital biomarkers should not be viewed simply as another technology investment.
They can become a strategic clinical development capability.
Companies that successfully integrate digital measurement into R&D may gain access to richer evidence, more patient-centric trial models, and potentially more responsive clinical endpoints.
This could influence decisions across the development lifecycle—from early proof-of-concept studies to pivotal trials and post-market evidence generation.
Digital biomarker strategies may also support differentiation.
As therapeutic markets become increasingly competitive, demonstrating how a treatment improves patients’ everyday lives can become commercially valuable alongside traditional measures of clinical efficacy.
The ability to generate high-quality real-world and digital evidence may therefore influence not only regulatory development but also market access and commercialization.
Consulting Angle: Moving From Technology Adoption to Evidence Strategy
For life sciences organizations, the strategic opportunity is not simply to add wearable devices to clinical trials.
The real challenge is building an integrated digital biomarker evidence strategy.
Before investing at scale, pharmaceutical and biotechnology companies should determine which digital measurements provide meaningful value for specific diseases, patient populations, and clinical endpoints.
Five areas deserve particular attention:
Clinical relevance: Does the digital biomarker measure an outcome that matters to patients and clinicians?
Validation: Can the measurement demonstrate sufficient reliability and reproducibility?
Regulatory alignment: Is there a clear pathway for using the measurement within clinical development?
Technology integration: Can devices, platforms, and data systems operate effectively within existing trial infrastructure?
Scalability: Can the approach be deployed consistently across sites, countries, and diverse patient populations?
Companies that address these questions early can avoid treating digital biomarkers as isolated technology experiments and instead build scalable capabilities around digital clinical evidence.
The Future of Clinical Trials May Be Continuous
Digital biomarkers are unlikely to replace traditional clinical endpoints entirely.
Instead, their greatest potential may come from complementing conventional assessments with continuous, objective, and real-world measurements.
The future clinical trial could look significantly different from today’s model.
Patients may participate partly from home. Wearables may continuously capture relevant physiological signals. AI may identify patterns in real time. Researchers may receive a richer picture of treatment response between clinical visits.
This transformation could make clinical development more connected, patient-centric, and data-driven.
But technology alone will not determine success.
The organizations that lead this transition will be those that successfully combine clinical science, digital technology, regulatory strategy, data analytics, and patient-centered trial design.
Digital biomarkers may indeed revolutionize clinical trials—but their greatest impact will come when continuous data becomes trusted, actionable evidence that improves both drug development decisions and patient outcomes.